Implications of metabotropic glutamate receptor structures for drug discovery in neurotherapeutics

References

• Gomez-Mancilla B, Berry-Kravis E, Hagerman R, et al. Development of mavoglurant and its potential for the treatment of fragile X syndrome. Expert Opin Investig Drugs 2014;23(1):125-34
   PubMed Web of Science ®Google Scholar
• Petrov D, Pedros I, de Lemos M, et al. Mavoglurant as a treatment for Parkinson’s disease. Expert Opin Investig Drugs 2014;23(8):1165-79
   PubMed Web of Science ®Google Scholar
• Rascol O, Fox S, Gasparini F, et al. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Park Relat Disord 2014;20(9):947-56
   PubMed Web of Science ®Google Scholar
• Marin J, Goadsby P. Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine? Expert Opin Investig Drugs 2010;19(4):555-61
   PubMed Web of Science ®Google Scholar
• Flor PJ, Acher FC. Orthosteric versus allosteric GPCR activation: the great challenge of group-III mGluRs. Biochem Pharmacol. [Internet] 2012.84(4):414-24. Available from: www.ncbi.nlm.nih.gov/pubmed/22554564
   Google Scholar
• Borshell N, Congreve M. Valuation benefits of structure- enabled drug discovery. Nat Rev Drug Discov 2011;10:166
   PubMed Web of Science ®Google Scholar
• Li J, Liu X, Li S, et al. Identification of novel small molecules as inhibitors of hepatitis C virus by structure-based virtual screening. Int J Mol Sci [Internet] 2013.14(11):22845-56. Available from: www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3856094&tool=pmcentrez&rendertype=abstract
   Google Scholar
• Schindler T, Bornmann W, Pellicena P, et al. Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase. Science. [Internet] 2000.289(5486):1938-42. Available from: www.sciencemag.org/cgi/doi/10.1126/science.289.5486.1938
   Google Scholar
• Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: A Major Success of Structure-Assisted Drug Design. 1998;1
   Google Scholar
• Congreve M, Langmead C, Marshall FH. The use of GPCR structures in drug design. [Internet]. 1st ed. Elsevier Inc Available from: www.ncbi.nlm.nih.gov/pubmed/21907905
   Google Scholar
• Tate CG. A crystal clear solution for determining G-protein-coupled receptor structures. Trends Biochem Sci [Internet] 2012.37(9):343-52. Available from: www.ncbi.nlm.nih.gov/pubmed/22784935
   Google Scholar
• Chae PS, Rasmussen SGF, Rana RR, et al. Maltose-neopentyl glycol (MNG) amphiphiles for solubilization, stabilization and crystallization of membrane proteins. Nat Methods [Internet] 2010.7(12):1003-8. Available from: www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3063152&tool=pmcentrez&rendertype=abstract
   Google Scholar
• Caffrey M, Cherezov V. Crystallizing membrane proteins using lipidic mesophases. Nat Protoc [Internet] 2009.4(5):706-31. Available from: www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2732203&tool=pmcentrez&rendertype=abstract
   Google Scholar
• Rosenbaum DM, Cherezov V, Hanson MA, et al. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science [Internet] 2007.318(5854):1266-73. Available from: www.ncbi.nlm.nih.gov/pubmed/17962519
   Google Scholar
• Rasmussen SGF, Choi H-J, Rosenbaum DM, et al. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature [Internet] 2007.450(7168):383-7. Available from: www.ncbi.nlm.nih.gov/pubmed/17952055
   Google Scholar
• Robertson N, Jazayeri A, Errey J, et al. The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery. Neuropharmacology [Internet] 2011.60(1):36-44. Available from: www.ncbi.nlm.nih.gov/pubmed/20624408
   Google Scholar
• Tate CG. A crystal clear solution for determining G-protein-coupled receptor structures. Trends Biochem Sci 2012;37:343-52
   Google Scholar
• Wu H, Wang C, Gregory K, et al. Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science 2014;344(6179):58-64
   PubMed Web of Science ®Google Scholar
• Doré AS, Okrasa K, Patel JC, et al. Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain. Nature [Internet] 2014.511(7511):557-62. Available from: www.ncbi.nlm.nih.gov/pubmed/25042998
   Google Scholar
• Bennett KA, Doré AS, Christopher JA, et al. Structures of mGluRs shed light on the challenges of drug development of allosteric modulators. Curr Opin Pharmacol [Internet] 2015.20:1-7. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1471489214001283
   Google Scholar
• Brien JAO, Lemaire WEI, Chen T, et al. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol Pharmacol 2003;64(3):731-40
   Google Scholar